Compare JBLU & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBLU | NUVB |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2002 | N/A |
| Metric | JBLU | NUVB |
|---|---|---|
| Price | $5.00 | $4.92 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $4.91 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 23.9M | 4.3M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,062,000,000.00 | N/A |
| Revenue This Year | $12.11 | $203.82 |
| Revenue Next Year | $6.75 | $58.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.87 | $1.57 |
| 52 Week High | $6.46 | $9.75 |
| Indicator | JBLU | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 53.69 |
| Support Level | $4.90 | $4.07 |
| Resistance Level | $5.15 | $5.16 |
| Average True Range (ATR) | 0.24 | 0.37 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 43.90 | 39.52 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.